Literature DB >> 17010601

Androgen receptor and vitamin D receptor gene polymorphisms and prostate cancer risk.

Patiyan Andersson1, Eberhard Varenhorst, Peter Söderkvist.   

Abstract

We study the CAG repeat region in exon 1 of the androgen receptor (AR) and the TaqI polymorphism in exon 9 of the vitamin D receptor (VDR) and the association with prostate cancer. 137 incidentally discovered, histologically verified prostate cancers were analysed for CAG repeat length in AR and genotype at the TaqI site of the VDR. 124 control subjects were analysed to determine the CAG repeat length and TaqI genotype determined for 176 control subjects. An unpaired t-test shows that the mean CAG repeat length was significantly (p<0.001) shorter among cases (20.1 repeats) compared with controls (22.5 repeats). Dividing the prostate cohort and controls into tertiles (< or = 19, 20-22, > or = 23 repeats) shows that short repeats are significantly more common among cases (odds ratio (OR) 4.45, p=0.00003). Genotype frequencies for the TaqI polymorphism reveals no significant differences between cases and controls. We conclude that men with a short CAG repeat in the androgen receptor gene have an increased risk of developing prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17010601     DOI: 10.1016/j.ejca.2006.06.030

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  18 in total

1.  The CAG repeat polymorphism of androgen receptor gene and prostate cancer: a meta-analysis.

Authors:  Mingliang Gu; Xiaoqun Dong; Xuezhi Zhang; Wenquan Niu
Journal:  Mol Biol Rep       Date:  2011-06-12       Impact factor: 2.316

2.  Involvement of different mechanisms for the association of CAG repeat length polymorphism in androgen receptor gene with prostate cancer.

Authors:  Xueying Mao; Jie Li; Xingxing Xu; Lara K Boyd; Weiyang He; Elzbieta Stankiewicz; Sakunthala C Kudahetti; Guangwen Cao; Daniel Berney; Guosheng Ren; Xin Gou; Hongwei Zhang; Yong-Jie Lu
Journal:  Am J Cancer Res       Date:  2014-11-19       Impact factor: 6.166

3.  Androgen receptor CAG repeat length and association with prostate cancer risk: results from the prostate cancer prevention trial.

Authors:  Douglas K Price; Cindy H Chau; Cathee Till; Phyllis J Goodman; Caitlin E Baum; Sandy B Ockers; Bevin C English; Lori Minasian; Howard L Parnes; Ann W Hsing; Juergen K V Reichardt; Ashraful Hoque; Catherine M Tangen; Alan R Kristal; Ian M Thompson; William D Figg
Journal:  J Urol       Date:  2010-10-16       Impact factor: 7.450

4.  Ethnical disparities of prostate cancer predisposition: genetic polymorphisms in androgen-related genes.

Authors:  Jie Li; Emma Mercer; Xin Gou; Yong-Jie Lu
Journal:  Am J Cancer Res       Date:  2013-04-03       Impact factor: 6.166

Review 5.  Trinucleotide repeat instability via DNA base excision repair.

Authors:  Yanhao Lai; Jill M Beaver; Eduardo Laverde; Yuan Liu
Journal:  DNA Repair (Amst)       Date:  2020-09

6.  Coordination between polymerase beta and FEN1 can modulate CAG repeat expansion.

Authors:  Yuan Liu; Rajendra Prasad; William A Beard; Esther W Hou; Julie K Horton; Cynthia T McMurray; Samuel H Wilson
Journal:  J Biol Chem       Date:  2009-08-11       Impact factor: 5.157

Review 7.  Vitamin D receptor gene (VDR) associations with cancer.

Authors:  Martha L Slattery
Journal:  Nutr Rev       Date:  2007-08       Impact factor: 7.110

8.  Prostate cancer susceptibility Loci identified on chromosome 12 in African Americans.

Authors:  Carolina Bonilla; Stanley Hooker; Tshela Mason; Cathryn H Bock; Rick A Kittles
Journal:  PLoS One       Date:  2011-02-16       Impact factor: 3.240

9.  Androgen receptor polyglutamine repeat number: models of selection and disease susceptibility.

Authors:  Calen P Ryan; Bernard J Crespi
Journal:  Evol Appl       Date:  2012-06-11       Impact factor: 5.183

10.  Phase II trial of isoflavone in prostate-specific antigen recurrent prostate cancer after previous local therapy.

Authors:  John M Pendleton; Winston W Tan; Satoshi Anai; Myron Chang; Wei Hou; Kathleen T Shiverick; Charles J Rosser
Journal:  BMC Cancer       Date:  2008-05-11       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.